论文信息 - Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma - 字舞流文

Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma

J. Blay | P. Hammerman | A. Italiano | J. Tabernero | J. Soria | J. Infante | V. Moreno | P. Lara | A. Cervantes | E. Calvo | B. Zhong | A. Spira | R. Lauer | F. Luo | Hong Xie | N. Chan | J. Bussolari | A. Santiago-Walker | H. Xie